4//SEC Filing
Dillon Michael P. 4
Accession 0001567619-21-016927
CIK 0001676725other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 7:24 PM ET
Size
20.1 KB
Accession
0001567619-21-016927
Insider Transaction Report
Form 4
Dillon Michael P.
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-09-07$27.46/sh−116$3,185→ 78,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-07−116→ 66,119 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (116 underlying) - Exercise/Conversion
Common Stock
2021-09-08$11.08/sh+4,313$47,788→ 90,173 total - Sale
Common Stock
2021-09-08$27.41/sh−11,184$306,559→ 78,989 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-08−7,071→ 59,048 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (7,071 underlying) - Exercise/Conversion
Common Stock
2021-09-08$4.31/sh+7,071$30,476→ 85,860 total - Sale
Common Stock
2021-09-08$27.67/sh−200$5,534→ 78,789 total - Exercise/Conversion
Common Stock
2021-09-07$4.31/sh+116$500→ 78,905 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-08−4,313→ 24,937 totalExercise: $11.08Exp: 2029-03-13→ Common Stock (4,313 underlying)
Footnotes (5)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F5]25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Documents
Issuer
IDEAYA Biosciences, Inc.
CIK 0001676725
Entity typeother
Related Parties
1- filerCIK 0001777415
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 7:24 PM ET
- Size
- 20.1 KB